Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms

International Journal of Cancer

Volumn 137, Issue 2, 2015, Pages 289-298

  Matte, Isabelle ^a   Lane, Denis ^a   Laplante, Claude ^a   Garde Granger, Perrine ^a   Rancourt, Claudine ^a   Piché, Alain ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Akt; ascites; cMet; ERK1 2; hepatocyte growth factor; mesothelial cells; ovarian cancer

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; 2-(4-(3-QUINOLIN-6-YLMETHYL-3H-(1,2,3)TRIAZOLO(4,5-B)PYRAZIN-5-YL)PYRAZOL-1-YL)ETHANOL; AUTACOID; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; MAPK1 PROTEIN, HUMAN; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ARTICLE; ASCITES; CANCER GROWTH; CELL MIGRATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MESOTHELIUM CELL; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TUMOR GROWTH; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL MOTION; DRUG EFFECTS; EPITHELIUM CELL; IMMUNOBLOTTING; METABOLISM; OVARY TUMOR; PATHOLOGY; PERITONEAL CAVITY; PHOSPHORYLATION;

ASCITES; CELL MOVEMENT; CELLS, CULTURED; CYTOKINES; ENZYME ACTIVATION; EPITHELIAL CELLS; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOBLOTTING; INFLAMMATION MEDIATORS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OVARIAN NEOPLASMS; PERITONEAL CAVITY; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; PYRAZINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRIAZOLES;

EID: 84929252279     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29385     Document Type: Article

References (36)

1. Partridge EE, Barnes MN,. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J Clin 1999; 49: 297-320.
2. Kipps E, Tan DS, Kaye SB,. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 2013; 13: 273-82.
3. Bhowmick NA, Moses HL,. Tumor-stroma interactions. Curr Opin Genet Dev 2005; 15: 97-101.
4. Liotta LA, Kohn EC,. The microenvironment of the tumor-host interface. Nature 2001; 411: 375-9.
5. Schauer IG, Sood AK, Mok S, et al. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia 2011; 13: 393-405.
6. Ren J, Xiao YJ, Singh LS, et al. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 2006; 66: 3006-14.
7. Rafi A, Mirshahi P, Poupot M, et al. Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours. PLoS One 2008; 3: e3894.
8. Pasquet M, Golzio M, Mery E, et al. Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis. Int J Cancer 2010; 126: 2090-101.
9. Davidson B,. Malignant effusions: from diagnosis to biology. Diagn Cytopathol 2004; 31: 246-54.
10. Bian D, Su S, Mahanivong C, et al. Lysophosphatidic acid stimulates ovarian cancer migration via a Ras-MEK kinase 1 pathway. Cancer Res 2004; 64: 4209-17.
11. Yamada T, Sato K, Komachi M, et al. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem 2004; 279: 6595-605.
12. Matte I, Lane D, Bachvarov D, et al. Role of malignant ascites on human peritoneal mesothelial cells and their gene expression profiles. BMC Cancer 2014; 14: 288.
13. Kajiyama H, Kikkawa F, Maeda O, et al. Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients. Oncology 2002; 63: 158-65.
14. Stadlmann S, Amberger A, Pollheimer J, et al. Ovarian carcinoma cells and IL-1β-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions. Gynecol Oncol 2005; 93: 784-9.
15. Yao Q, Qu X, Yang Q, et al. CLIC4 mediates TGF-β1-induced fibroblast-to-myoblast transdifferentiation in ovarian cancer. Oncol Rep 2009; 22: 541-8.
16. Matte I, Lane D, Laplante C, et al. Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res 2012; 2: 566-80.
17. Mills GB, Moolenaar WH,. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3: 582-91.
18. Lane D, Matte I, Rancourt C, et al. The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer. J Ovarian Res 2010; 3: 1.
19. Lane D, Robert V, Grondin R, et al. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer 2007; 121: 1227-37.
20. Lane D, Goncharenko-Khaider N, Rancourt C, et al. Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene 2010; 29: 3519-31.
21. Goncharenko-Khaider N, Matte I, Lane D, et al. Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. Mol Cancer 2012; 11: 84.
22. Puiffe ML, Le Page C, Filali-Mouhim A, et al. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 2007; 9: 820-9.
23. Mills GB, May C, Hill M, et al. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest 1990; 86: 851-5.
24. Matsumoto K, Nakamura T,. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer 2006; 119: 477-83.
25. Eder JP, Vande Woude GF, Boerner SA, et al. Novel therapeutic inhibitors of the c-Met signalling pathway in cancer. Clin Cancer Res 2009; 15: 2207-14.
26. Sawada K, Radjabi AR, Shinomiya N, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007; 67: 1670-79.
27. Sowter HM, Corps AN, Smtih SK,. Hepatocyte growth factor (HGF) in epithelial ovarian tumor fluids stimulates the migration of ovarian cancer cells. Int J Cancer 1999; 83: 473-80.
28. Jo M, Stolz DB, Esplen JE, et al. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000; 275: 8806-11.
29. Zou HY, Li Q, Lee JH, et al. Sensitivity of selected tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther 2012; 11: 1036-47.
30. Xiao GH, Jeffers M, Bellacosa A, et al. Anti-apoptotic signalling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 2001; 98: 247-52.
31. Parsons SL, Lang MW, Steele RJ,. Malignant ascites: a 2-year review for a teaching hospital. Eur J Surg Oncol 1996; 22: 237-9.
32. Ayantunde AA, Parsons SL,. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007; 18: 945-9.
33. Schauer IG, Sood AK, Mok S, et al. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia 2011; 13: 393-405.
34. Kwon Y, Smith BD, Zhou Y, et al. Effective inhibition of c-MET-mediating signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment. Oncogene 2013. doi: 10.1038/onc.2013.539.
35. Tokunou M, Niki T, Eguchi K, et al. c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma. Am J Pathol 2001; 158: 1451-63.
36. Zhang H, Liu X, Liu Y, et al. Epithelial-mesenchymal transition of rat peritoneal mesothelial cells via Rhoα/Rock pathway. In Vitro Cell Dev Biol 2011; 47: 165-72.